Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937558 · ClinicalTrials.gov registry record · Phase 2
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
A Phase 2 study, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02937558: Completed Phase 2 study, sponsored by Xeris Pharmaceuticals.
NCT02937558 is a Phase 2 study that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02937558, a Phase 2 study, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children \< 1 year of age with congenital hyperinsulinism.
Primary Outcome
Change from baseline in glucose infusion rate (GIR) will be determined for each subject at 24 and 48 hours from the start of blinded treatment. Subjects with a decrease in GIR ≥ 20% at 24 hours, and ≥ 33% at 48 hours will be considered to have had a clinically meaningful treatment response.
Interventions
- OTHER Placebo
- DRUG Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
What the finished NCT02937558 record still lists
NCT02937558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02937558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02937558 about?
NCT02937558 is a clinical study titled "CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism". This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children \< 1 year ...
What is the current status of trial NCT02937558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2016-10. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02937558?
The interventions under investigation include: Placebo (OTHER), Glucagon (DRUG).
Who is sponsoring clinical trial NCT02937558?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02937558's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia